Influenza vaccination in patients with juvenile idiopathic arthritis under different treatments: safety and immune response
Authors' conclusion
The present study demonstrates adequate seroprotection rates against influenza A in immunosuppressed children with JIA. The trivalent vaccine had good immunogenicity and was safe to use in both JIA treatment groups.
Study context
- Population
- Children with juvenile idiopathic arthritis (JIA) receiving inactivated influenza vaccination while treated with methotrexate (MTX) or biological therapychildren with JIA
- Participants
- 41 children
- Comparison
- JIA on MTX vs JIA on biological therapy vs healthy children, after single-dose trivalent influenza vaccine (TIV)
- Healthy childrenn = 22reference
- Outcome
- Seroconversion and seroprotection, influenza A
Methodological detailsSerological tests at baseline and 4 and 12 weeks after vaccination
- Serological tests at baseline and 4 and 12 weeks after vaccination
Main finding
As reported in the abstract
- Seroconversion and seroprotection for influenza A observed in all 41 children with JIA and the 22 healthy children
Further findings
Seroconversion, influenza B
- No adequate seroconversion rates detected in any of the groups
Lymphocyte subpopulations
- No significant differences across time points and groups; no non-specific immune activation suggested
Safety
Relapses or influenza infection after vaccination
- None
- 0
Original publication
Influenza vaccination in patients with juvenile idiopathic arthritis under different treatments: safety and immune response. Pediatr Rheumatol Online J. Published 25 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →